Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Liabilities and Shareholders Equity (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Liabilities and Shareholders Equity over the past 3 years, most recently at $277.2 million for Q4 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $277.2 million for Q4 2025, up 70.16% from a year ago — trailing twelve months through Dec 2025 was $909.8 million (up 96.29% YoY), and the annual figure for FY2025 was $277.2 million, up 70.16%.
  • Liabilities and Shareholders Equity for Q4 2025 was $277.2 million at Tonix Pharmaceuticals Holding, up from $252.4 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for TNXP hit a ceiling of $277.2 million in Q4 2025 and a floor of $70.3 million in Q2 2024.
  • Median Liabilities and Shareholders Equity over the past 3 years was $161.3 million (2023), compared with a mean of $167.2 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: plummeted 55.99% in 2024 and later skyrocketed 166.49% in 2025.
  • Tonix Pharmaceuticals Holding's Liabilities and Shareholders Equity stood at $154.5 million in 2023, then rose by 5.46% to $162.9 million in 2024, then surged by 70.16% to $277.2 million in 2025.
  • The last three reported values for Liabilities and Shareholders Equity were $277.2 million (Q4 2025), $252.4 million (Q3 2025), and $187.4 million (Q2 2025) per Business Quant data.